ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
PMN310 potential best in class antibody candidate for treatment of Alzheimer’s disease
TORONTO and CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the initiation of producer cell line development for PMN310. This key first step in the manufacturing of antibody therapeutics will be carried out by Selexis, SA, using Selexis’ proprietary SUREtechnology Platform™.
“ProMIS’ lead antibody program PMN310 offers potential “best in class” antibody therapy for Alzheimer’s disease,” stated ProMIS Executive Chairman Eugene Williams. “With initiation of producer cell line development, we are re-focusing our efforts on advancing PMN310 into clinical development with the support of a distinguished Boston-based group of investors.”
After two years of setbacks in the Alzheimer’s disease (AD) field, 2021 has seen tremendous progress and reason for optimism. Positive data from Lilly and Cassava, in addition to Biogen’s June 7 PDUFA date for aducanumab, portend potential positive momentum for AD patients.
ProMIS is poised to contribute to the field. As stated by Gene Williams, “Using our proprietary discovery platform we were able to create the PMN310 antibody so that it selectively targets only the toxic oligomers of amyloid-beta (A) and avoids undesirable binding to non-toxic forms of amyloid. We believe this high degree of selectivity of PMN310 may offer significant differentiation in terms of efficacy and safety compared to less selective antibody products from Biogen, Eisai, and Lilly.”
PMN310, is a humanized monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of A, a recognized root cause of AD. Importantly, PMN310 does not appreciably bind to A plaque or vascular deposits of A thereby reducing the likelihood of brain swelling (edema), a dose-limiting side effect observed with non-selective therapeutic antibodies that interact with A plaque. The current cell line development is based on an IgG1 isotype format (rather than the originally envisaged IgG4 format) as data from the scientific literature indicate that an IgG1 isotype may achieve greater efficacy via engagement of the immune system to clear damaging A oligomers from the brain.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences, please consult the Company’s website at: www.promisneurosciences.com
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
On substantial participation16.6.2021 19:10:00 CEST | Press release
JSC Olainfarm has received announcements on substantial participation from Anna Emīlija Maligina, SIA “OLMAFARM” and SIA “FARMA FUND”. The received announcements (in Latvian) are attached. Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Phone: +371 29178878 Email: firstname.lastname@example.org Attachments Pazinojums_lidzdaliba_SIA Farma Fund_Olainfarm_AEM_OLMAFARM_2021_06_16.docxPazinojums_lidzdaliba_SIA OLMAFARM_Olainfarm_2021_06_16.docxPazinojums_lidzdaliba_AEM_Olainfarm_2021_06_16.docx
GeoJunxion (GOJXN.AS) announces the nomination of a new CEO and CBO16.6.2021 18:00:00 CEST | Press release
Capelle aan den IJssel, The Netherlands – 16 June 2021 – GeoJunxion (GOJXN.AS) is pleased to announce today that the Supervisory Board has decided to nominate Mr. I. Vleeschouwers as its new CEO, and Mr. F. Altamura as its new CBO (Chief Business Officer). Ivo Vleeschouwers currently serving as GeoJunxion’s CFO, has been nominated as permanent CEO. He will be combining the CEO and CFO functions going forward. Mr. Vleeschouwers together with the former CEO (Mr. Jaccoud), has been an integral part in spearheading GeoJunxion’s transformation from a traditional digital map supplier, focused on one-off large deals, to a premium location content and location intelligence service provider, with a “data as a service” revenue model. In light of the recent successes of this on-going change such as the closing of location intelligence service contracts for a value exceeding Euro 600K (see press release dated 6 May 2021) and increased market interest in the new product portfolio (Eco Alert Zones a
Staten lånar 10 miljarder kronor på 50 år till 1,386 % ränta16.6.2021 18:00:00 CEST | Pressemelding
Statenlånar 10 miljarder kronor på 50 år till 1,386% ränta Riksgälden lånadei dag upp 10 miljarder kronor till en ränta på 1,386 procent i den planerade emissionen av en50-årig statsobligation. Den nya obligationen blir det längsta låneti Sveriges statsskuld. Totalt deltog ett 80-tal investerare med en budvolym på drygt 52 miljarder kronor i emissionen som genomfördes som en syndikering. Det innebär att en grupp banker sålde obligationen till villkor som Riksgälden godkänt. Obligationen prissattes till 45 räntepunkter över marknadsräntan på den tidigare längsta svenska statsobligationen som förfaller om drygt 24 år. – Jag är glad att vi har kunnat förlänga den svenska statspapperskurvan till 50 år genom denna transaktion. Med Sveriges starka statsfinanser som grund visar vi än en gång att Riksgälden kan attrahera en bred investerarbas, säger Johan Bergström, tillförordnad upplåningschef på Riksgälden. Riksgälden kommer att bygga upp den utestående volymen i den nya obligationen SGB 106
Sweden raises SEK 10 billion at 1.386 % with 50-year bond16.6.2021 18:00:00 CEST | Press release
Sweden raises SEK 10 billion at1.386%with 50-year bond The Kingdom of Sweden raised SEK 10 billion at a yield of 1.386 per cent in the planned sale of a 50-year government bond. The new bond will be the longest outstanding loan in Sweden’s central government debt. More than 80 investors participated in the syndicated sale with the total bid volume reaching above SEK 52 billion. Syndication means that a group of banks executes the transaction at terms approved by the issuer. The final pricing was fixed at 45 basis points above the yield on the Swedish government bond that was formerly the longest, maturing in just over 24 years. – I am pleased that we were able to extend the Swedish government bond curve to 50 years through this transaction. With Sweden’s strong state finances as a foundation, we have again shown that we can attract a broad investor base, says Johan Bergström, Acting Head of Funding at the Swedish National Debt Office. The Debt Office will gradually build up the outstan
Auction details treasury bills16.6.2021 16:20:00 CEST | Press release
Auction date June 23, 2021 Maturity date Issue volume, SEK million Days (Act/360) ISIN code 2021-10-20 15,000 114SE0016275457 Settlement date June 28, 2021 Bids have to be entered by 11.00 on June 23, 2021 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 Fo@riksgalden.se
Halmstads Energi och Miljö strengthens power grid for the future – with data analytics16.6.2021 14:23:17 CEST | Press release
Having a security of supply in the power grid of 99,99 percent does not make Halmstads Energi och Miljö AB (HEM) to sit back and relax. Instead, the regional Swedish energy company has declared to make digitalization of the power grid their next step forward. Installing the dInsight Analytics Platform from Dlaboratory Sweden AB (publ) has allowed the company to analyze grid data in-depth and take proactive measures to prevent outages and make grid investments. - The advantage of dLab’s system is that we can find faults in the grid, incidents, and disturbances, before they develop into major outages. This is how we want to work, proactively, before anything has happened, says Jonas Stenberg, electrical engineer at Halmstads Energi och Miljö. The collaboration between HEM and dLab started out as a pilot project in 2018 but by now dLab’s digital solution covers about 70 percent of HEM’s power grid. - It is truly inspiring to learn about HEM’s ambitions within digitalization, and their det
Skyharbour Expands its Current Drill Program at its High Grade Moore Uranium Project, Saskatchewan16.6.2021 14:00:00 CEST | Press release
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V:SYH)(OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce that it is expanding its current diamond drilling program at its flagship 35,705 hectare Moore Uranium Project, located approximately 15 kilometres east of Denison Mine's Wheeler River project and near regional infrastructure on the southeast side of the Athabasca Basin, Saskatchewan. The current drilling program at Moore is progressing well and has provided significant encouragement to expand the current 3,500 metres drilling program to a total of 5,000 metres in 12 to 14 holes. This fully funded and permitted program will focus on following-up on existing unconformity and basement-hosted targets along the high grade Maverick structural corridor as well as newly defined targets at the Grid Nineteen area. Moore Uranium Project Claims Map: https://skyharbourltd.com/_resources/maps/MooreLakeRegionalTenure-v1.jpg Winter/S